IP Library › Granted Patent US 12,458,693
Granted Patent B2
US 12,458,693 · App. 18/140,121 · Granted Nov 4, 2025

Methods of treating iron overload with a BMP inhibitor

Inventors: Jasbir S. Seehra (Lexington, MA); Jennifer Lachey (Lincoln, MA); Christopher R. Rovaldi (Swampscott, MA); Claudia Ordonez (Lexington, MA)
Assignee: Keros Therapeutics, Inc.
A61K39/3955A61P7/00A61K31/519C07K16/2863C07K16/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,693
App. No.
18/140,121
Granted
Nov 4, 2025
Kind
B2
Abstract

The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors. The invention also features methods of decreasing iron levels in a subject by administering BMP or hepcidin inhibitors.

Claims (33)

1. A method of treating a subject identified as having iron overload, comprising administering to the subject a therapeutically effective amount of a BMP inhibitor, wherein the BMP inhibitor is an ALK2 antibody or an ALK2 binding fragment thereof comprising:

(a) a light chain CDR1 comprising the amino acid sequence SGSSSNIGSNYVS (SEQ ID NO:1); a light chain CDR2 comprising the amino acid sequence VLIYKNNHRPS (SEQ ID NO:24); a light chain CDR3 comprising the amino acid sequence ASWDHSDRFYV (SEQ ID NO:4); a heavy chain CDR1 comprising the amino acid sequence GGTFSSYGVS (SEQ ID NO:31); a heavy chain CDR2 comprising the amino acid sequence WMGGIIPHFGIANYAQKFQG (SEQ ID NO:36); and a heavy chain CDR3 comprising the amino acid sequence EIGSLDI (SEQ ID NO:13);

(b) a light chain CDR1 comprising the amino acid sequence SGDSIPSFFAS (SEQ ID NO:18); a light chain CDR2 comprising the amino acid sequence LVIYRDSNRPS (SEQ ID NO:25); a light chain CDR3 comprising the amino acid sequence YVTAPWKSIW (SEQ ID NO:5); a heavy chain CDR1 comprising the amino acid sequence GFTFSSHAMS (SEQ ID NO:32); a heavy chain CDR2 comprising the amino acid sequence WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO:37); and a heavy chain CDR3 comprising the amino acid sequence DYGVAFAY (SEQ ID NO:14);

(c) a light chain CDR1 comprising the amino acid sequence SGDNIGTKYAY (SEQ ID NO:19); a light chain CDR2 comprising the amino acid sequence LVIYGDSDRPS (SEQ ID NO:26); a light chain CDR3 comprising the amino acid sequence YSADAQQMKA (SEQ ID NO:6); a heavy chain CDR1 comprising the amino acid sequence GFTFNSSAMS (SEQ ID NO:33); a heavy chain CDR2 comprising the amino acid sequence WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO:38); and a heavy chain CDR3 comprising the amino acid sequence DYGGLKFDY (SEQ ID NO:15);

(d) a light chain CDR1 comprising the amino acid sequence SGDNLRKYSAH (SEQ ID NO:20); a light chain CDR2 comprising the amino acid sequence LVIYYDNKRPS (SEQ ID NO:27); a light chain CDR3 comprising the amino acid sequence QVYASVHRM (SEQ ID NO:7); a heavy chain CDR1 comprising the amino acid sequence GGTFSSYAIH (SEQ ID NO:34); a heavy chain CDR2 comprising the amino acid sequence WMGRIIPDFGTANYAQKFQG (SEQ ID NO:39); and a heavy chain CDR3 comprising the amino acid sequence GPTQAIHYFAY (SEQ ID NO:16);

(e) a light chain CDR1 comprising the amino acid sequence SGDSLGSKSVH (SEQ ID NO:21); a light chain CDR2 comprising the amino acid sequence LVIYRDSKRPS (SEQ ID NO:28); a light chain CDR3 comprising the amino acid sequence QTYDWSHFGW (SEQ ID NO:8); a heavy chain CDR1 comprising the amino acid sequence GFTFSSAAMH (SEQ ID NO:35); a heavy chain CDR2 comprising the amino acid sequence WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and a heavy chain CDR3 comprising the amino acid sequence AGFILGSLGVAWMDV (SEQ ID NO:17);

(f) a light chain CDR1 comprising the amino acid sequence RASQGISGNWLT (SEQ ID NO:40); a light chain CDR2 comprising the amino acid sequence LLIYDASNLQS (SEQ ID NO:41); a light chain CDR3 comprising the amino acid sequence HQSYRGPM (SEQ ID NO:42); a heavy chain CDR1 comprising the amino acid sequence GFTFGRFVMH (SEQ ID NO:43); a heavy chain CDR2 comprising the amino acid sequence WVSVIGYSGSSTYYADSVKG (SEQ ID NO:44); and a heavy chain CDR3 comprising the amino acid sequence EPGYYYPSGYYRGPGYWMDV (SEQ ID NO:45);

(g) a light chain CDR1 comprising the amino acid sequence SGDNIRKKYVH (SEQ ID NO:46); a light chain CDR2 comprising the amino acid sequence LVIYRDSNRPS (SEQ ID NO:47); a light chain CDR3 comprising the amino acid sequence SSAGRDNY (SEQ ID NO:48); a heavy chain CDR1 comprising the amino acid sequence GFTFSSSAMH (SEQ ID NO:49); a heavy chain CDR2 comprising the amino acid sequence WVSVIHYDSSETYYADSVKG (SEQ ID NO:50); and a heavy chain CDR3 comprising the amino acid sequence DRYFFDV (SEQ ID NO:51);

(h) a light chain CDR1 comprising the amino acid sequence SGDALRYYIAH (SEQ ID NO:52); a light chain CDR2 comprising the amino acid sequence LVIYYNNNRPS (SEQ ID NO:53); a light chain CDR3 comprising the amino acid sequence QSYGPGSV (SEQ ID NO:54); a heavy chain CDR1 comprising the amino acid sequence GFTFSDYAMH (SEQ ID NO:55); a heavy chain CDR2 comprising the amino acid sequence WVSSIFYSGSNTYYADSVKG (SEQ ID NO:56); and a heavy chain CDR3 comprising the amino acid sequence PKSYASGPFAY (SEQ ID NO:57); or

(i) a light chain CDR1 comprising the amino acid sequence SGSSSNIGQNYVS (SEQ ID NO:58); a light chain CDR2 comprising the amino acid sequence LLIYDNSKRPS (SEQ ID NO:59); a light chain CDR3 comprising the amino acid sequence SSWDLLSKSR (SEQ ID NO:60); a heavy chain CDR1 comprising the amino acid sequence GGTFSTHAIS (SEQ ID NO:61); a heavy chain CDR2 comprising the amino acid sequence WMGLIQPRFGTANYAQKFOR (SEQ ID NO:62); and a heavy chain CDR3 comprising the amino acid sequence DYYGGMAY (SEQ ID NO:63).

2. The method of claim 1 , wherein the subject has hemochromatosis.

3. The method of claim 1 , wherein the iron overload is caused by iron supplementation.

4. The method of claim 1 , wherein the subject has anemia.

5. The method of claim 4 , wherein the anemia is associated with chronic kidney disease.

6. The method of claim 1 , wherein the iron overload is caused by a blood transfusion.

7. The method of claim 1 , wherein the BMP inhibitor is administered in combination with a chelator.

8. The method of claim 7 , wherein the BMP inhibitor and the chelator are administered concurrently.

9. The method of claim 7 , wherein the BMP inhibitor is administered before the chelator.

10. The method of claim 9 , wherein the BMP inhibitor and the chelator are administered within 24 hours of each other.

11. The method of claim 7 , wherein the BMP inhibitor is administered after the chelator.

12. The method of claim 7 , wherein the chelator is deferoxamine, deferasirox, or deferiprone.

13. The method of claim 1 , wherein the subject undergoes phlebotomy.

14. A method of decreasing iron in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a BMP inhibitor, wherein the BMP inhibitor is an ALK2 antibody or an ALK2 binding fragment thereof comprising:

(a) a light chain CDR1 comprising the amino acid sequence SGSSSNIGSNYVS (SEQ ID NO:1); a light chain CDR2 comprising the amino acid sequence VLIYKNNHRPS (SEQ ID NO:24); a light chain CDR3 comprising the amino acid sequence ASWDHSDRFYV (SEQ ID NO:4); a heavy chain CDR1 comprising the amino acid sequence GGTFSSYGVS (SEQ ID NO:31); a heavy chain CDR2 comprising the amino acid sequence WMGGIIPHFGIANYAQKFQG (SEQ ID NO:36); and a heavy chain CDR3 comprising the amino acid sequence EIGSLDI (SEQ ID NO:13);

(b) a light chain CDR1 comprising the amino acid sequence SGDSIPSFFAS (SEQ ID NO:18); a light chain CDR2 comprising the amino acid sequence LVIYRDSNRPS (SEQ ID NO:25); a light chain CDR3 comprising the amino acid sequence YVTAPWKSIW (SEQ ID NO:5); a heavy chain CDR1 comprising the amino acid sequence GFTFSSHAMS (SEQ ID NO:32); a heavy chain CDR2 comprising the amino acid sequence WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO:37); and a heavy chain CDR3 comprising the amino acid sequence DYGVAFAY (SEQ ID NO:14);

(c) a light chain CDR1 comprising the amino acid sequence SGDNIGTKYAY (SEQ ID NO:19); a light chain CDR2 comprising the amino acid sequence LVIYGDSDRPS (SEQ ID NO:26); a light chain CDR3 comprising the amino acid sequence YSADAQQMKA (SEQ ID NO:6); a heavy chain CDR1 comprising the amino acid sequence GFTFNSSAMS (SEQ ID NO:33); a heavy chain CDR2 comprising the amino acid sequence WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO:38); and a heavy chain CDR3 comprising the amino acid sequence DYGGLKFDY (SEQ ID NO:15);

(d) a light chain CDR1 comprising the amino acid sequence SGDNLRKYSAH (SEQ ID NO:20); a light chain CDR2 comprising the amino acid sequence LVIYYDNKRPS (SEQ ID NO:27); a light chain CDR3 comprising the amino acid sequence QVYASVHRM (SEQ ID NO:7); a heavy chain CDR1 comprising the amino acid sequence GGTFSSYAIH (SEQ ID NO:34); a heavy chain CDR2 comprising the amino acid sequence WMGRIIPDFGTANYAQKFQG (SEQ ID NO:39); and a heavy chain CDR3 comprising the amino acid sequence GPTQAIHYFAY (SEQ ID NO:16);

(e) a light chain CDR1 comprising the amino acid sequence SGDSLGSKSVH (SEQ ID NO:21); a light chain CDR2 comprising the amino acid sequence LVIYRDSKRPS (SEQ ID NO:28); a light chain CDR3 comprising the amino acid sequence QTYDWSHFGW (SEQ ID NO:8); a heavy chain CDR1 comprising the amino acid sequence GFTFSSAAMH (SEQ ID NO:35); a heavy chain CDR2 comprising the amino acid sequence WVSVISSDGGSTYYADSVKG (SEQ ID NO:12); and a heavy chain CDR3 comprising the amino acid sequence AGFILGSLGVAWMDV (SEQ ID NO:17);

(f) a light chain CDR1 comprising the amino acid sequence RASQGISGNWLT (SEQ ID NO:40); a light chain CDR2 comprising the amino acid sequence LLIYDASNLQS (SEQ ID NO:41); a light chain CDR3 comprising the amino acid sequence HQSYRGPM (SEQ ID NO:42); a heavy chain CDR1 comprising the amino acid sequence GFTFGRFVMH (SEQ ID NO:43); a heavy chain CDR2 comprising the amino acid sequence WVSVIGYSGSSTYYADSVKG (SEQ ID NO:44); and a heavy chain CDR3 comprising the amino acid sequence EPGYYYPSGYYRGPGYWMDV (SEQ ID NO:45);

(g) a light chain CDR1 comprising the amino acid sequence SGDNIRKKYVH (SEQ ID NO:46); a light chain CDR2 comprising the amino acid sequence LVIYRDSNRPS (SEQ ID NO:47); a light chain CDR3 comprising the amino acid sequence SSAGRDNY (SEQ ID NO:48); a heavy chain CDR1 comprising the amino acid sequence GFTFSSSAMH (SEQ ID NO:49); a heavy chain CDR2 comprising the amino acid sequence WVSVIHYDSSETYYADSVKG (SEQ ID NO:50); and a heavy chain CDR3 comprising the amino acid sequence DRYFFDV (SEQ ID NO:51);

(h) a light chain CDR1 comprising the amino acid sequence SGDALRYYIAH (SEQ ID NO:52); a light chain CDR2 comprising the amino acid sequence LVIYYNNNRPS (SEQ ID NO:53); a light chain CDR3 comprising the amino acid sequence QSYGPGSV (SEQ ID NO:54); a heavy chain CDR1 comprising the amino acid sequence GFTFSDYAMH (SEQ ID NO:55); a heavy chain CDR2 comprising the amino acid sequence WVSSIFYSGSNTYYADSVKG (SEQ ID NO:56); and a heavy chain CDR3 comprising the amino acid sequence PKSYASGPFAY (SEQ ID NO:57); or

(i) a light chain CDR1 comprising the amino acid sequence SGSSSNIGQNYVS (SEQ ID NO:58); a light chain CDR2 comprising the amino acid sequence LLIYDNSKRPS (SEQ ID NO:59); a light chain CDR3 comprising the amino acid sequence SSWDLLSKSR (SEQ ID NO:60); a heavy chain CDR1 comprising the amino acid sequence GGTFSTHAIS (SEQ ID NO:61); a heavy chain CDR2 comprising the amino acid sequence WMGLIQPRFGTANYAQKFOR (SEQ ID NO:62); and a heavy chain CDR3 comprising the amino acid sequence DYYGGMAY (SEQ ID NO:63).

15. The method of claim 14 , wherein the subject has iron overload.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2023
From: SEEHRA, JASBIR S.; LACHEY, JENNIFER; ROVALDI, CHRISTOPHER R.; ORDONEZ, CLAUDIA
To: KEROS THERAPEUTICS, INC.
Reel/Frame 064845/0910 →
Continuity (7)
Continuation PCTUS2021057974 · Nov 4, 2021
Provisional Application 63208410 · Jun 8, 2021
Provisional Application 63187386 · May 11, 2021
Provisional Application 63121319 · Dec 4, 2020
Provisional Application 63111471 · Nov 9, 2020
Provisional Application 63109861 · Nov 4, 2020
Related Publication 20230406956A1 · Dec 21, 2023
References Cited (186)
US 7534764B2 · Ganz et al. · 2009 [cited by applicant]
US 7820163B2 · Leung et al. · 2010 [cited by applicant]
US 7968091B2 · Woolf et al. · 2011 [cited by applicant]
US 8163711B2 · Nakayama et al. · 2012 [cited by applicant]
US 8268799B2 · Nakayama et al. · 2012 [cited by applicant]
US 8329174B2 · Leung et al. · 2012 [cited by applicant]
US 8338377B2 · Seehra · 2012 [cited by applicant]
US 8455428B2 · Grinberg et al. · 2013 [cited by applicant]
US 8470799B2 · Nakayama et al. · 2013 [cited by applicant]
US 8507501B2 · Yu et al. · 2013 [cited by applicant]
US 8609817B2 · Leung et al. · 2013 [cited by applicant]
US 8629250B2 · Sasu et al. · 2014 [cited by applicant]
US 8637023B2 · Lin et al. · 2014 [cited by applicant]
US 8765129B2 · Leung et al. · 2014 [cited by applicant]
US 8791250B2 · Nakayama et al. · 2014 [cited by applicant]
US 8796199B2 · Grinberg et al. · 2014 [cited by applicant]
US 8841431B2 · Sell et al. · 2014 [cited by applicant]
US 8895002B2 · Lin et al. · 2014 [cited by applicant]
US 9045484B2 · Yu et al. · 2015 [cited by applicant]
US 9051382B2 · Trentmann et al. · 2015 [cited by applicant]
US 9228188B2 · Bettencourt et al. · 2016 [cited by applicant]
US 9315577B2 · Foltz et al. · 2016 [cited by applicant]
US 9556251B2 · Lin et al. · 2017 [cited by applicant]
US 9610356B2 · Hohlbaum et al. · 2017 [cited by applicant]
US 9636398B2 · Beligere et al. · 2017 [cited by applicant]
US 9657098B2 · Westerman et al. · 2017 [cited by applicant]
US 9682983B2 · Alimardanov et al. · 2017 [cited by applicant]
US 9708379B2 · Lin et al. · 2017 [cited by applicant]
US 9914762B2 · Seehra · 2018 [cited by applicant]
US 9950034B2 · Hohlbaum et al. · 2018 [cited by applicant]
US 9988627B2 · Baryza et al. · 2018 [cited by applicant]
US 10017516B2 · Alimardanov et al. · 2018 [cited by applicant]
US 10023621B2 · Kumar et al. · 2018 [cited by applicant]
US 10118958B2 · Mueller et al. · 2018 [cited by applicant]
US 10233186B2 · Brooijmans et al. · 2019 [cited by applicant]
US 10260068B2 · Hino et al. · 2019 [cited by applicant]
US 10323088B2 · Westerman · 2019 [cited by applicant]
US 10428148B2 · Katagiri et al. · 2019 [cited by applicant]
US 10513521B2 · Lee et al. · 2019 [cited by applicant]
US 10669277B2 · Wilson et al. · 2020 [cited by applicant]
US 10765626B2 · Kumar et al. · 2020 [cited by applicant]
US 10822403B2 · Mueller et al. · 2020 [cited by applicant]
US 10934359B2 · Roy et al. · 2021 [cited by applicant]
US 11026947B2 · Yu et al. · 2021 [cited by applicant]
US 11654147B2 · Yu et al. · 2023 [cited by applicant]
US 12071438B2 · Bethune et al. · 2024 [cited by applicant]
US 20040096990A1 · Geacintov et al. · 2004 [cited by applicant]
US 20070004618A1 · Ganz et al. · 2007 [cited by applicant]
US 20100062001A1 · Reiter et al. · 2010 [cited by applicant]
US 20110182904A1 · Zimmerman et al. · 2011 [cited by applicant]
US 20120030780A1 · Ma · 2012 [cited by applicant]
US 20120196853A1 · Durrenberger et al. · 2012 [cited by applicant]
US 20120202806A1 · Durrenberger et al. · 2012 [cited by applicant]
US 20120214798A1 · Durrenberger et al. · 2012 [cited by applicant]
US 20120214803A1 · Buhr et al. · 2012 [cited by applicant]
US 20130089560A1 · Chartier-Courtaud et al. · 2013 [cited by applicant]
US 20140057970A1 · Schwobel et al. · 2014 [cited by applicant]
US 20150291675A1 · Trentmann et al. · 2015 [cited by applicant]
US 20160046633A1 · Alimardanov et al. · 2016 [cited by applicant]
US 20160075772A1 · Hatsell et al. · 2016 [cited by applicant]
US 20160115167A1 · Yu et al. · 2016 [cited by applicant]
US 20160115209A1 · Knopf et al. · 2016 [cited by applicant]
US 20160186172A1 · Bettencourt et al. · 2016 [cited by applicant]
US 20160257958A1 · Sell et al. · 2016 [cited by applicant]
US 20170183411A1 · Lin et al. · 2017 [cited by applicant]
US 20180057586A1 · Westerman et al. · 2018 [cited by applicant]
US 20180118835A1 · Katagiri et al. · 2018 [cited by applicant]
US 20180171005A1 · Cong et al. · 2018 [cited by applicant]
US 20180180614A1 · Crowe, Jr. et al. · 2018 [cited by applicant]
US 20190055192A1 · Dalton et al. · 2019 [cited by applicant]
US 20190218262A1 · Rajasekhar Suragani et al. · 2019 [cited by applicant]
US 20200040054A1 · Du et al. · 2020 [cited by applicant]
US 20200095250A1 · Vechorkin et al. · 2020 [cited by applicant]
US 20200179389A1 · Yu et al. · 2020 [cited by applicant]
US 20200199131A1 · Pan et al. · 2020 [cited by applicant]
US 20200331908A1 · Brubaker et al. · 2020 [cited by applicant]
US 20210154195A1 · Chen et al. · 2021 [cited by applicant]
US 20210238185A1 · Bethune et al. · 2021 [cited by applicant]
US 20210253720A1 · Seehra et al. · 2021 [cited by applicant]
US 20210393605A1 · Seguy et al. · 2021 [cited by applicant]
US 20220401445A1 · Seehra et al. · 2022 [cited by applicant]
US 20230000869A1 · Yu et al. · 2023 [cited by applicant]
US 20230372390A1 · Seehra et al. · 2023 [cited by applicant]
US 20230398118A1 · Seehra et al. · 2023 [cited by applicant]
US 20250034148A1 · Seehra et al. · 2025 [cited by applicant]
EP 3252074A1 · 2017 [cited by applicant]
WO WO0218382A1 · 2002 [cited by applicant]
WO WO2006052913A1 · 2006 [cited by applicant]
WO WO2007028212A1 · 2007 [cited by applicant]
WO WO2008097461A2 · 2008 [cited by applicant]
WO WO2008124768A1 · 2008 [cited by applicant]
WO WO2009058797A1 · 2009 [cited by applicant]
WO WO2009114180A1 · 2009 [cited by applicant]
WO WO2010017047A1 · 2010 [cited by applicant]
WO WO2010091150A1 · 2010 [cited by applicant]
WO WO2010124874A1 · 2010 [cited by applicant]
WO WO2011023722A1 · 2011 [cited by applicant]
WO WO2011029832A1 · 2011 [cited by applicant]
WO WO2012022742A1 · 2012 [cited by applicant]
WO WO2012064805A1 · 2012 [cited by applicant]
WO WO2012065059A2 · 2012 [cited by applicant]
WO WO2012065852A2 · 2012 [cited by applicant]
WO WO2012150973A1 · 2012 [cited by applicant]
WO WO2013016452A2 · 2013 [cited by applicant]
WO WO2013090635A2 · 2013 [cited by applicant]
WO WO2013187416A1 · 2013 [cited by applicant]
WO WO2014071015A1 · 2014 [cited by applicant]
WO WO2014138088A1 · 2014 [cited by applicant]
WO WO2014160203A2 · 2014 [cited by applicant]
WO WO2015051135A2 · 2015 [cited by applicant]
WO WO2015148654A1 · 2015 [cited by applicant]
WO WO2015187977A1 · 2015 [cited by applicant]
WO WO2016011019A1 · 2016 [cited by applicant]
WO WO2016039796A2 · 2016 [cited by applicant]
WO WO2016054406A1 · 2016 [cited by applicant]
WO WO2016130897A1 · 2016 [cited by applicant]
WO WO2016165808A1 · 2016 [cited by applicant]
WO WO2017184942A1 · 2017 [cited by applicant]
WO WO2018067873A2 · 2018 [cited by applicant]
WO WO2018200855A1 · 2018 [cited by applicant]
WO WO2018209242A1 · 2018 [cited by applicant]
WO WO2018232094A1 · 2018 [cited by applicant]
WO WO2019058062A1 · 2019 [cited by applicant]
WO WO2019102256A1 · 2019 [cited by applicant]
WO WO2019191204A1 · 2019 [cited by applicant]
WO WO2020068729A1 · 2020 [cited by applicant]
WO WO2020086730A1 · 2020 [cited by applicant]
WO WO2020086736A1 · 2020 [cited by applicant]
WO WO2020086963A1 · 2020 [cited by applicant]
WO WO2020118011A1 · 2020 [cited by applicant]
WO WO2020201038A1 · 2020 [cited by applicant]
WO WO2021030386A1 · 2021 [cited by applicant]
WO WO2021062171A1 · 2021 [cited by applicant]
WO WO2021067670A1 · 2021 [cited by applicant]
WO WO2021163170A1 · 2021 [cited by applicant]
WO WO2022240948A1 · 2022 [cited by applicant]
WO WO2023081212A1 · 2023 [cited by applicant]
Sanchez-Duffhues et al, 2020. Bone. 138: 115472. [cited by examiner]
Benjamini et al, 1991. Immunology: A Short Course, 2nd edition, p. 40 only. [cited by examiner]
Ferrara et al (2015. mAbs. 7(1):32-41). [cited by examiner]
Barton et al., “Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases,” Am J Hematol. 81(10):760-7 (2006). [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/057974, dated Mar. 2, 2022 (8 pages). [cited by applicant]
Ensan et al., “Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma,” J Med Chem. 63(9):4978-4996 (2020). [cited by applicant]
Berge et al., “Pharmaceutical salts,” J Pharm Sci. 66(1):1-19 (1977). [cited by applicant]
Stieger et al., “Recrystallization of Active Pharmaceutical Ingredients,” Crystallization—Science and Technology. 183-201 (Sep. 2012) (23 pages). [cited by applicant]
Saal et al., “Pharmaceutical salts: a summary on doses of salt formers from the Orange Book,” Eur J Pharm Sci. 49(4):614-23 (Jul. 2013). [cited by applicant]
Morrell et al., “Targeting BMP signalling in cardiovascular disease and anaemia,” Nat Rev Cardiol. 13(2):106-20 (with supplemental material) (2016) (32 pages). [cited by applicant]
Saeed et al., “Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease,” J Am Coll Cardiol. 72(2):156-169 (with supplemental material) (Jul. 2018) (31 pages). [cited by applicant]
Ali et al., “Bone morphogenetic proteins and their antagonists: current and emerging clinical uses,” Br J Pharmacol. 171(15):3620-32 (2014). [cited by applicant]
Vela, Driton, “Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology,” Lab Invest. 98(3):315-326 (Mar. 2018). [cited by applicant]
Abdelmahmuod et al., “Iron Deficiency Anemia-Induced Lymphocytopenia in a Young Female,” Case Rep Oncol. 13(2):793-797 (Jul. 2020) (5 pages). [cited by applicant]
“Sideroblastic anemia,” Wikipedia, <https://en.wikipedia.org/w/index.php?title=Sideroblastic_anemia&oldid=1056240400>, retrieved May 12, 2023 (Nov. 20, 2021) (6 pages). [cited by applicant]
Singer et al., “Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures,” PLoS One. 14(9): e0222944 (Sep. 2019) (14 pages). [cited by applicant]
Hopkins, “Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015),” Expert Opin Ther Pat. 26(10):1115-28 (2016) (15 pages). [cited by applicant]
Sun et al., “Mucus binding protein [ [cited by applicant]
Olsen et al., “BMPR2 inhibits activin- and BMP-signaling via wild type ALK2,” J Cell Sci 131(11):jcs213512 (2018) (39 pages). [cited by applicant]
Asshoff et al., “Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents,” Blood. 129(13):1823-1830 (Mar. 2017). [cited by applicant]
Kaplan et al., “From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva,” Expert Opin Orphan Drugs. 1(8):637-649 (Aug. 2013). [cited by applicant]
Pang et al., “ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva,” Bone. 92:29-36 (Aug. 2, 2016). [cited by applicant]
Santa Cruz Biotechnology, Inc., Datasheet for “ACTR-I (C-5): sc-374523,” <https://datasheets.scbt.com/sc-374523.pdf>, retrieved on May 25, 2018 (1 page). [cited by applicant]
Santa Cruz Biotechnology, Inc., Datasheet for “ACTR-IA (Y0311): sc-73676,” <https://datasheets.scbt.com/sc-73676.pdf>, retrieved on May 23, 2018 (1 page). [cited by applicant]
Katagiri et al., “Development of blocking monoclonal antibodies against ALK2, which is a type I receptor for BMPs,” Annual Meeting of the American Society for Bone and Mineral Research, Colorado Convention Center, Denve… [cited by applicant]
Aykul et al. “Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1,” J Clin Invest. 132(12): (14 pages) (Published Jun. 15, 2022). [cited by applicant]
Harth et al. “A Selection Fit Mechanism in BMP Receptor IA as a Possible Source for BMP Ligand-Receptor Promiscuity,” PLoS One. 5(9): 1-13 (Published Sep. 28, 2010). [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Immunology, 79, pp. 1979-1983 (1982) (5 pages). [cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem Biophys Res Commun. 307(1):198-205 (2003). [cited by applicant]
Holm et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Mol Immunol. 44(6):1075-84 (2007). [cited by applicant]
Steinbicker et al., “Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation,” Blood. 117(18):4915-4923 (May 2011) (9 pages). [cited by applicant]
Babitt et al., “Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance,” J Clin Invest. 117(7):1933-1939 (Jul. 2007) (7 pages). [cited by applicant]
Kovac et al., “Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels,” (Letters to the Editor) haematologica. 101:e173-176 (May 2016) (4 pages). [cited by applicant]
Hixon et al., “DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Is Predicted to be Efficacious at Low Doses in Humans as Determined By Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling in Non-Clin… [cited by applicant]
Cooke et al., “A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates,” Blood. 122(17):3054-3061 (Oct. 2013) (8 pages). [cited by applicant]
Sasu et al., “Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia,” Blood. 115(17):3616-3624 (Apr. 2010) (9 pages). [cited by applicant]
Vadhan-Raj et al., “A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia,” Journal of Hematology & Oncology. 10:73 (Mar. 2017) (12 pages). [cited by applicant]
Akinc et al., “Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia,” Blood. 118(21):688 (Abstract) (Nov. 2011) (2 pages). [cited by applicant]
Hohlbaum et al., “Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations,” Blood. 118(21):687 (Abstract) (Nov… [cited by applicant]
Van Eijk et al., “Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia,” Crit Car… [cited by applicant]
Angmo et al., “Identification of Guanosine 5′-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway,” Sci Rep. 7:40097 (Jan. 2017) (12 p… [cited by applicant]
Mueller et al., “3NH7: Crystal structure of the neutralizing Fab fragment AbD1556 bound to the BMP type I receptor IA,” RCSB PDB, <https://www.rcsb.org/structure/3NH7>, Released Oct. 27, 2010, (Revised Nov. 1, 2023) (5 … [cited by applicant]
U.S. Appl. No. 18/289,039, Seehra et al. [cited by applicant]
“7 Risk Factors That Could Lead to Anemia,” Lindenberg Cancer & Hematology Center. <https://lindenbergcancer.com/blog/7-risk-factors-that-could-lead-to-anemia/>, accessed Feb. 19, 2019 (10 pages). [cited by applicant]
“Myelodysplastic/myeloproliferative neoplasm, unclassifiable,” National Cancer Institute. <https://seer.cancer.gov/seertools/hemelymph/51f6cf59e3e27c3994bd5438/>, 2020 (8 pages). [cited by applicant]
“Myeloproliferative Disorders (MPDs) Causes, Symptoms, and Treatment Options,” UPMC Hillman Cancer Center. <https://hillman.upmc.com/cancer-care/blood/types/mpd> accessed Apr. 29, 2020 (3 pages). [cited by applicant]
Boergermann et al., “Dorsomorphin and LDN-193189 inhibit BMP-medated Smad, p38 and Akt signalling in C2C12 cells.” The International Journal of Biochemistry & Cell Biology, 42(11): 1802- 1807 (2010) (13 pages). [cited by applicant]
Hong et al., “Applications of Small Molecule BMP Inhibitors in Physiology and Disease, ” Cytokine and Growth Factor Reviews, 20(5-6): 409-418 (2009) (25 pages). [cited by applicant]
Sanvitale et al., “A new class of small molecule inhibitor of BMP signaling,” PLoS One. 8(4):e62721 (2013) (11 pages). [cited by applicant]